Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. CP Pharmaceuticals, Ltd.
WARNING LETTER
•CP Pharmaceuticals, Ltd.•July 29, 2010

CP Pharmaceuticals, Ltd. – FDA Warning Letter, Jul 29, 2010

Record Details

On October 29, 2010, the FDA issued a Warning Letter to CP Pharmaceuticals, Ltd. following a July 22-29, 2010 inspection of their Wrexham, UK pharmaceutical manufacturing facility. The inspection revealed significant violations of Current Good Manufacturing Practice (CGMP) regulations for Finished Pharmaceuticals (21 CFR Parts 210 and 211), rendering their drug products adulterated.

Key violations included: 1. **Aseptic Processing Control Deficiencies (21 CFR § 211.42(c)):** Lack of documentary evidence for in-situ air pattern analysis (smoke studies) in critical areas, failure to ensure aseptic conditions in production rooms and equipment, inadequate environmental monitoring practices (e.g., mold contamination in Class 100 room, poor wall conditions in freeze dryer room), and inadequate aseptic techniques by operators, including unmonitored personnel sampling. 2. **Inadequate Investigations (21 CFR § 211.192):** Failure to routinely perform species identification of yeast and molds, lack of raw data for a failed November 2009 media fill, and absence of challenge testing for sterility media with environmental isolates. 3. **Insufficient Laboratory Controls (21 CFR § 211.160(b)):** Incomplete or unavailable validation data for several laboratory methods (e.g., total viable aerobic

Company
CP Pharmaceuticals, Ltd.
Inspection date
July 29, 2010
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Richard L. Friedman (Director)
View Company Profile

ID · 1a77ce49-2183-48b5-a1cf-454186efca72

Violation Codes7
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 21121 CFR 211.42(c)21 CFR 211.19221 CFR 211.160(b)21 U.S.C. 381(a)(3)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore CP Pharmaceuticals, Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.